EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische Studie

Abbreviated Dual Antiplatelet Therapy in Patients With High Bleeding Risk Undergoing PCI of Bifurcation Lesions: A Prespecified Substudy of the MASTER DAPT Trial

Bernard Chevalier, Davide Cao iD, Pieter C Smits iD, Philippe Brunel, Enrico Frigoli, Dik Heg iD, Yoshiharu Higuchi iD, Floris Kauer, Antonio Landi, Renato D Lopes iD, Vicente Mainar, Mamas Mamas iD und 14 weitere

Circulation: Cardiovascular Interventions · 2026

DOI: 10.1161/circinterventions.125.016222 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Circulation: Cardiovascular Interventions, 2026. Verfasst von Bernard Chevalier und 25 weiteren Autor:innen. Beteiligte Einrichtung: Institut Cardiovasculaire Paris-Sud, Hôpital Privé Jacques Cartier, Ramsay-Santé, Massy, France (B.C.). Hauptthemen laut MEDLINE: Platelet Aggregation Inhibitors, Hemorrhage, Percutaneous Coronary Intervention, Dual Anti-Platelet Therapy. Die Arbeit nennt 38 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Coronary stenting of bifurcation lesions has been associated with an increased risk of thrombotic events. However, the optimal duration of dual antiplatelet therapy (DAPT) after treatment of bifurcations, particularly among patients with high bleeding risk, is unknown. We aimed to evaluate the safety and efficacy of abbreviated DAPT in patients with high bleeding risk undergoing percutaneous coronary intervention (PCI) of bifurcation lesions. METHODS: The MASTER DAPT trial (Management of High Bleeding Risk Patients Post Bioresorbable Polymer Coated Stent Implantation With an Abbreviated Versus Standard DAPT Regimen) randomized patients with high bleeding risk who were free from ischemic or bleeding events after 1 month of PCI to discontinue DAPT (abbreviated regimen) or continue DAPT for a minimum of 2 additional months (standard regimen). Coprimary outcomes were net adverse clinical outcomes events, major adverse cardiac and cerebral events, and BARC (Bleeding Academic Research Consortium) type 2, 3, or 5 bleeding at 335 days after randomization. This prespecified substudy evaluates the outcomes of abbreviated versus standard DAPT according to treatment of bifurcation lesions. RESULTS: Of the 4579 patients randomized, 976 (21.2%) underwent bifurcation PCI. Net adverse clinical event and major adverse cardiac and cerebral events did not differ between abbreviated and standard DAPT in both patients with (hazard ratio [HR], 0.98 [95% CI, 0.73–1.17] and HR, 0.92 [95% CI, 0.63–1.54], respectively) and without bifurcation PCI (HR, 1.14 [95% CI, 0.67–1.93] and HR, 0.96 [95% CI, 0.74–1.25]; P interaction=0.803 and 0.563, respectively). Abbreviated DAPT consistently reduced BARC 2, 3, or 5 bleeding in patients with (HR, 0.83 [95% CI, 0.53–1.30]) or without (HR, 0.65 [95% CI, 0.51–0.82]) bifurcation ( P interaction=0.321). CONCLUSIONS: Among patients with high bleeding risk with or without bifurcation PCI, abbreviated DAPT was associated with lower bleeding risk without an excess of ischemic or net adverse events compared with standard DAPT. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03023020.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Platelet Aggregation InhibitorsHemorrhagePercutaneous Coronary InterventionDual Anti-Platelet TherapyCoronary Artery DiseaseAspirinHumansFemaleMaleTreatment OutcomeRisk FactorsAgedTime FactorsRisk AssessmentMiddle AgedDrug Administration ScheduleDrug-Eluting StentsAbsorbable ImplantsTreatment InterruptionClopidogrelCoronary Thrombosis

Stichwörter der Autor:innen

dual anti-platelet therapypercutaneous coronary intervention

Substanzen

Platelet Aggregation InhibitorsAspirinClopidogrel

Autor:innen und Institutionen

  • Institut Cardiovasculaire Paris-Sud, Hôpital Privé Jacques Cartier, Ramsay-Santé, Massy, France (B.C.).
  • Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, MI, Italy (D.C.).
  • Department of Cardiology, Humanitas Gavazzeni, Bergamo, Italy (D.C.).
  • Department of Cardiology, Maasstad Hospital, Rotterdam, the Netherlands (P.C.S., V.P.).
  • Cardiology Department, Hôpital Privé Dijon-Bourgogne, Dijon, France (P.B.).
  • Cardiocentro Ticino Institute, Ente Ospedaliero Cantonale (EOC), Lugano, Switzerland (E.F., A.L., M.V.).

ORCID-Profile: Davide Cao, Pieter C Smits, Dik Heg, Yoshiharu Higuchi, Renato D Lopes, Mamas Mamas, Eùgene P McFadden, Ajit Mulassari, Bernhard Reimers, Imre Ungi, Clemens von Birgelen, Valeria Paradies, Marco Valgimigli

Zitieren

APA

Chevalier, B., Cao, D., Smits, P. C., Brunel, P., Frigoli, E., Heg, D., Higuchi, Y., Kauer, F., Landi, A., Lopes, R. D., Mainar, V., Mamas, M., Mateev, H., McDonald, J., McFadden, E. P., Mulassari, A., Munir, S., Polad, J., Reimers, B., …, & MASTER DAPT Investigators (2026). Abbreviated Dual Antiplatelet Therapy in Patients With High Bleeding Risk Undergoing PCI of Bifurcation Lesions: A Prespecified Substudy of the MASTER DAPT Trial. Circulation: Cardiovascular Interventions. https://doi.org/10.1161/circinterventions.125.016222

Vancouver

Chevalier B, Cao D, Smits PC, Brunel P, Frigoli E, Heg D, et al. Abbreviated Dual Antiplatelet Therapy in Patients With High Bleeding Risk Undergoing PCI of Bifurcation Lesions: A Prespecified Substudy of the MASTER DAPT Trial. Circulation: Cardiovascular Interventions. 2026. doi:10.1161/circinterventions.125.016222

BibTeX
@article{Chevalier2026,
  author = {Chevalier, Bernard and Cao, Davide and Smits, Pieter C and Brunel, Philippe and Frigoli, Enrico and Heg, Dik and Higuchi, Yoshiharu and Kauer, Floris and Landi, Antonio and Lopes, Renato D and Mainar, Vicente and Mamas, Mamas and Mateev, Hristo and McDonald, John and McFadden, Eùgene P and Mulassari, Ajit and Munir, Shahzad and Polad, Jawed and Reimers, Bernhard and Sardella, Gennaro and Ungi, Imre and von Birgelen, Clemens and Weidinger, Franz and Paradies, Valeria and Valgimigli, Marco and MASTER DAPT Investigators, MASTER DAPT Investigators},
  title = {Abbreviated Dual Antiplatelet Therapy in Patients With High Bleeding Risk Undergoing PCI of Bifurcation Lesions: A Prespecified Substudy of the MASTER DAPT Trial},
  journal = {Circulation: Cardiovascular Interventions},
  year = {2026},
  doi = {10.1161/circinterventions.125.016222}
}
Kostenlos starten →